ripekg:evaluation/RIPEA62FEC5B159F50CEC |
prov:wasInformedBy |
ripekg:evidence-aggregation/RIPEA62FEC5B159F50CEC |
ripekg:evidence-aggregation/RIPEA62FEC5B159F50CEC |
rdf:type |
rdfs:Resource |
ripekg:evidence-aggregation/RIPEA62FEC5B159F50CEC |
rdf:type |
owl:Thing |
ripekg:evidence-aggregation/RIPEA62FEC5B159F50CEC |
rdf:type |
ripe:EvidenceAggregationEvidence aggregation |
ripekg:evidence-aggregation/RIPEA62FEC5B159F50CEC |
rdf:type |
tido:Activity |
ripekg:evidence-aggregation/RIPEA62FEC5B159F50CEC |
prov:startedAtTime |
2025-11-17T13:15:02.436304Z |
ripekg:evidence-aggregation/RIPEA62FEC5B159F50CEC |
prov:wasAssociatedWith |
ripekg:automated-agent/inspect-ai/1.0.0INSPECT-AI 1.0.0 |
ripekg:evidence-aggregation/RIPEA62FEC5B159F50CEC |
prov:wasAssociatedWith |
ripekg:automated-agent/inspect-ai/1.0.0INSPECT-AI |
ripekg:evidence-aggregation/RIPEA62FEC5B159F50CEC |
tido:contributesTo |
ripekg:research-integrity-assessment/RIPEA62FEC5B159F50CEC |
ripekg:publication-details/RIPEA62FEC5B159F50CECOnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial |
prov:wasGeneratedBy |
ripekg:evidence-aggregation/RIPEA62FEC5B159F50CEC |
ripekg:registry-evidence/RIPEA62FEC5B159F50CEC |
prov:wasGeneratedBy |
ripekg:evidence-aggregation/RIPEA62FEC5B159F50CEC |
ripekg:study-design-evidence/RIPEA62FEC5B159F50CEC |
prov:wasGeneratedBy |
ripekg:evidence-aggregation/RIPEA62FEC5B159F50CEC |